WASHINGTON, D.C. — John Carreyrou’s 2015 exposé "Bad Blood" has re-entered top-tier bestseller lists following the release of a new documentary by Nathan Fielder. The book details the fraud at Theranos, a startup that once valued at $9 billion based on false claims of medical technology capabilities.

The resurgence in interest coincides with the premiere of "You Can See Everything," a film by the creator of "The Rehearsal." Fielder’s work offers a retrospective look at the collapse of Elizabeth Holmes, the former CEO of Theranos. The documentary’s release has driven significant traffic to the original reporting, causing the hardcover and digital editions to climb Amazon’s charts within days of its availability.

Carreyrou’s original reporting revealed that Theranos’ blood-testing devices did not function as advertised. Instead, the company used standard commercial machines while telling investors and customers otherwise. This deception allowed the company to raise over $700 million in venture capital before federal authorities intervened. The case became a landmark example of corporate fraud in the biotechnology sector.

Key Takeaways

• "Bad Blood" re-entered Amazon’s bestseller lists immediately following the release of Nathan Fielder’s documentary on Elizabeth Holmes.
• Theranos was valued at approximately $9 billion in 2014, a figure sustained by fraudulent claims about its proprietary blood-testing technology.
• The case resulted in criminal charges against Holmes, highlighting the risks of insufficient due diligence in venture capital investments.

Investment analysts note that the renewed public focus serves as a cautionary tale for current market participants. The Theranos scandal demonstrated how charismatic leadership and aggressive marketing could obscure fundamental technical flaws. Investors who backed the company during its peak lost substantial portions of their portfolios. Regulators in the U.S. have since tightened oversight for medical device claims to prevent similar breaches of consumer trust.

The documentary has sparked broader conversations about media’s role in uncovering corporate malfeasance. While Fielder’s film is a separate entity, its narrative aligns closely with Carreyrou’s investigative journalism. Critics argue that the initial cultural euphoria around Theranos contributed to its rapid rise, while its abrupt fall exposed the fragility of hype-driven business models. The continued relevance of the story underscores the enduring impact of investigative reporting on public policy and business ethics.

Legal proceedings against Holmes concluded in 2022, with a guilty plea and a four-year prison sentence. She was released in 2024 after serving part of her term. The company itself remains in litigation, with billions in damages still pending in civil suits. For now, "Bad Blood" stands as a definitive account of one of Silicon Valley’s most significant regulatory failures, reminding stakeholders of the critical importance of transparency in the life sciences industry.